AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug

Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease. Highmark said its contract with AstraZeneca is one of the first outcomes-based deals involving a respiratory drug and will apply to commercial members of its national and core markets in Pennsylvania, West Virginia and Delaware. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat AstraZeneca plc Source Type: news

Related Links:

Publication date: Available online 18 October 2018Source: The Lancet Respiratory MedicineAuthor(s): Samy Suissa, Sophie Dell'Aniello, Pierre ErnstSummaryBackgroundLong-acting β2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are the recommended initial maintenance treatment for chronic obstructive pulmonary disease (COPD), with almost all LABAs dispensed in fixed combination with inhaled corticosteroids (LABA-ICS). We compared the effectiveness and safety of LABA-ICS versus LAMA treatment initiation as a function of blood eosinophilia, a potential biomarker of ICS effectiveness, in a real-world settin...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
This article will summarize the structure and cellular function of MARCKS (also including MARCKS family proteins and MARCKS-like proteins 1 [MARCKSL1]). Evidence for MARCKS' role in several lung diseases, and the technological innovations that took MARCKS-targeting strategies from theoretical to therapeutic, will be discussed. Descriptions and updates from ongoing clinical trials that are investigating inhalation of a MARCKS-targeting peptide as therapy for patients with chronic bronchitis, lung cancer and ARDS will be provided. PMID: 30339463 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory Cell and Molecular Biology - Category: Molecular Biology Authors: Tags: Am J Respir Cell Mol Biol Source Type: research
ConclusionAn increased risk of TB development may persist for 3 years after stopping the ICS and the risk is higher in patients with COPD regardless of the type of ICS used.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Authors: Satia I, Badri H, Lahousse L, Usmani OS, Spanevello A PMID: 30310687 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Quintos A, Naranjo M, Kelly C, Quan SF, Sharma S Abstract PURPOSE: The HoSMed Database recently demonstrated a high prevalence of obstructive sleep apnea (OSA) in hospitalized obese patients. Based on a long-term follow-up, this study showed an improved survival among patients who were adherent with the therapy. In this post-hoc analysis we explore the characteristics, associations, and mortality outcome of OSA in the African American (AA) population. METHODS: These subset analyses included obese AA patients screened in the hospital as high-risk for OSA. Stepwise logistic regression analysis was used t...
Source: Journal of the National Medical Association - Category: General Medicine Tags: J Natl Med Assoc Source Type: research
th JA Abstract BACKGROUND: Cough is common in patients with lung cancer and current antitussive treatments are suboptimal. There is little published data describing cough in patients with lung cancer or work assessing clinical associations; the aim of the current is study is to fill that gap. METHODS: Longitudinal prospective observational single-cohort study over 60 days. Patients were assessed through self-reported validated scales and, in a subsample, ambulatory cough monitoring, at study entry (day 0), day 30 and day 60. RESULTS: At study entry, 177 patients were included and 153 provided data at day...
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
Publication date: Available online 9 October 2018Source: Pharmacological ResearchAuthor(s): D. Visca, P. Pignatti, A. Spanevello, E. Lucini, E. La RoccaAbstractDiabetes is a common metabolic disorder affecting the entire body with high morbidity and mortality worldwide. The major complications related to diabetes are mostly due to the macrovascular and microvascular bed impairment due to metabolic, hemodynamic and inflammatory factors. However, studies over the past decades have added also the lung as a target organ in both type 1 and type 2 diabetes. Diabetes has always been addressed as a major comorbidity conditioning t...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Albuminuria linked to increased risk for COPD and COPD - related events but not asthma
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Pulmonology, Critical Care, Journal, Source Type: news
ConclusionThe scope of the present review is to explore the inflammatory mechanism in airway diseases and highlight the influence of aging on airways ’ inflammation mechanism. The main goal of this review is to encourage research collaborations between experimentalist and modelers to promote our understanding of the physiological and pathological mechanisms that control inflammation in different airway diseases.
Source: Inflammation Research - Category: Research Source Type: research
CONCLUSIONS: Asthma patients with FAO had a smaller LA and higher resistance of the proximal airways than COPD patients. FEV1 and respiratory impedance correlated with airway morphology.
Source: Annals of Thoracic Medicine - Category: Respiratory Medicine Authors: Source Type: research
More News: Asthma | AstraZeneca | Chronic Obstructive Pulmonary | Contracts | Insurers | Respiratory Medicine | Symbicort